Cetuximab is FDA-approved for colorectal cancer and for head and neck cancer. It is not yet approved by the FDA for NSCLC.
What is the mechanism of action of cetuximab?
Cetuximab is an anticancer agent that works by inhibiting the growth and survival of epidermal growth factor receptor (EGFR)-expressing tumour cells with high specificity and higher affinity than epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-α), which are natural ligands of EGFR.
Is cetuximab a monoclonal antibody?
Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor expressing tumours.
Is cetuximab an immunotherapy?
Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
What is cetuximab approved for?
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor with the following FDA-approved indications: colorectal cancer, metastatic, KRAS wild-type (without mutation), and head and neck cancer (squamous cell).
How long does cetuximab take to work?
When you have cetuximab It takes about 2 hours the first time you have it. If you don’t have any problems, the following treatments take an hour. How long you have cetuximab depends on your cancer type.
What type of anticancer therapy is cetuximab?
Drug type: Cetuximab is an anti-cancer (“anti-neoplastic”) targeted therapy. This medication is classified as a “monoclonal antibody” and “Epidermal Growth Factor Receptor (EGFR) Inhibitor.” (For more detail, see “How this drug works” section below).
How long can you take cetuximab?
The treatment break rule refers to NHS England’s policy imposed on advanced bowel cancer drugs cetuximab and panitumumab, where planned breaks from treatment longer than six weeks are not allowed. Should a break be taken longer than this time period, funding for treatment is no longer provided by NHS England.
How much does cetuximab cost?
All further doses are 250 mg/m2 cetuximab given weekly. £178.10 per 20-ml vial and £890.50 per 100-ml vial (excluding VAT, ‘British national formulary’ [BNF] online October 2015).
How long can you be on cetuximab?
The treatment break rule refers to NHS England’s policy imposed on advanced bowel cancer drugs cetuximab and panitumumab, where planned breaks from treatment longer than six weeks are not allowed.
How successful is cetuximab?
Cetuximab also has activity as monotherapy in patients with recurrent and/or metastatic SCCHN who had failed platinum-based chemotherapy,. with a 12.6% response rate, disease control rate of 46%, and median response duration of ~ 6 months.
Is cetuximab FDA approved?
FDA approves Erbitux (cetuximab) to treat patients with advanced colorectal cancer that has spread to other parts of the body.
What are the clinical studies on cetuximab used to treat?
Clinical studies are ongoing of cetuximab in combination with radiation therapy and/or platinum in patients with squamous cell head and neck cancer, as well as cetuximab in combination with various antineoplastic agents in the treatment of non-small cell lung cancer and pancreatic cancer.
What is the response rate for cetuximab in colorectal cancer?
The overall response rate in 2 Phase II trials using the conventional dosing regimen of cetuximab to treat EGFR-expressing, metastatic colorectal cancer that was refractory to irinotecan therapy ranged from 9% to 12%. The drug was well tolerated with proper administration precautions.
Does cetuximab interact with irinotecan to cause toxic effects?
Toxic effects were more frequent in the combination-therapy group, but their severity and incidence were similar to those that would be expected with irinotecan alone. Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer.
How is Karnofsky (cetuximab) administered?
Randomization was performed by a minimization technique, with stratification according to Karnofsky performance status, previous treatment with or without prior use of oxaliplatin, and treatment center. Cetuximab was given at an initial dose of 400 mg per square meter, followed by weekly infusions of 250 mg per square meter.
